A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Telisotuzumab Adizutecan
DRUG: Standard of Care

Sponsor

AbbVie